Mycoplasma infections in children: an update by Anna R Cappiello et al.
MEETING ABSTRACT Open Access
Mycoplasma infections in children: an update
Anna R Cappiello1, Maria F Mastrototaro1, Mariacristina Pignatelli2, Gianluca Piccolo2, Iolanda Chinellato3,
Fabio Cardinale4*
From 70th Congress of the Italian Society of Pediatrics, Joint National Meeting SIP, SICuPP, SITIP
Palermo, Italy. 11-14 June 2014
Mycoplasma pneumoniae (MP) is a human bacterium that
lacks a cell wall and is adapted to life as an obligate patho-
gen in the respiratory tract [1]. MP is responsible of
20-40% of all community acquired pneumonia (CAP) and
is often associated with other airway disorders. Extrapul-
monary manifestations are supposed to be sequelae of
primary MP infections [2]. MP is believed to first act as an
extracellular parasite. However the microbial factors
responsible for the observed host cell injury have not been
satisfactorily determined [3]. In 2006, a 68-kDa protein
CARDS-Tx has been identified [2] from Kannan and
others, with a strong cytolytic and vacuolizating activity.
Techasaernsiri et al. demonstrates that CARDS-Tx con-
centrations in BAL of mice inoculated intranasally with
three different MP strains, was directly linked to the ability
of specific MP strains to colonize, replicate, persist and eli-
cit lung histopathology damage [3]. Furthermore Medina
et al. found that CARDS-Tx can induce increased expres-
sion of IL4, IL13 and Th-2 chemokines, causing cellular
inflammatory response, mucus metaplasia and increase in
airway hyperreactivity [4].
On the basis of this observation some authors suggest
the use of systemic steroids in order to diminish the host
response in MP infection. Observational data, also, indi-
cate that the addition of systemic steroids to antibiotics
may improve the outcome of severe MP pneumonia.
Tagliabue et al. demonstrates, in mice, that combination
therapy with clarithromycin and dexamethasone is more
effective in reducing MP induced pulmonary inflammation
than either clarithromycin alone or dexamethasone alone.
The authors, however, conclude that more controlled clin-
ical studies in humans are necessary [5].
Macrolide (ML) are recognized as first-choice agents
for MP infections. In 2000, however, MP showing
resistance to macrolides was isolated from clinical sam-
ples obtained from Japanese children with CAP. Since
then, prevalence of ML resistant MP isolates in pediatric
patients has increased rapidly worldwide.
ML inhibit MP protein synthesis by binding to domain
V of 23S rRNA at nucleotide positions 2063 and 2064.
Mutations at A2063 or A2064 confer the highest resis-
tance to these antimicrobials [6].
On the basis of studies of the prevalence of ML resis-
tance Principi et al suggest that in countries with low
incidence of ML-resistant MP strains no change in ML
prescription is initially needed. Nevertheless, in countries
in which ML-resistant MP strains are very common,
replacement of a ML with a tetracyclines or fluoroquino-
lones should be considered also based on the severity of
the disease [7].
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